Company Overview

Niagen Bioscience, Inc. (trading under the ticker NAGE) is a U.S.-based life sciences and nutraceutical company focused on the research, development, and commercialization of nicotinamide adenine dinucleotide (NAD⁺)–related products for healthy aging and cellular health. The company operates primarily within the dietary supplements, consumer health, and bioscience research industries. Its core commercial focus is nicotinamide riboside (NR), a patented form of vitamin B3 designed to increase NAD⁺ levels in the body, which are associated with cellular energy, metabolism, and aging-related biological processes.

The company’s primary revenue driver is the sale and licensing of its proprietary NR ingredient, marketed under the flagship consumer brand Tru Niagen®, as well as ingredient sales to third-party brands and research institutions. Niagen Bioscience serves health-conscious consumers, academic and clinical researchers, and commercial partners seeking NAD⁺-related solutions. The company positions itself as a science-first organization with a substantial portfolio of issued and pending patents around NR, supported by published clinical research and regulatory approvals in multiple jurisdictions. The business originated as ChromaDex Corporation, founded in 1999, and later evolved from a reference standards and analytical services company into a focused NAD⁺ bioscience company, culminating in a corporate rebranding to Niagen Bioscience, Inc.; the exact timing of the legal name and ticker change is reported consistently in public filings but may vary slightly across market data providers.

Business Operations

Niagen Bioscience operates through integrated business lines centered on consumer products, ingredient supply, and scientific research and licensing. The Consumer Products segment generates revenue primarily through direct-to-consumer and e-commerce sales of Tru Niagen®, while the Ingredients segment supplies NR to select global partners for inclusion in dietary supplements. A smaller but strategically important portion of revenue comes from licensing and royalties, tied to intellectual property related to NR production and use.

Operations span both domestic and international markets, with manufacturing conducted through qualified third-party manufacturers under strict quality and regulatory standards. The company controls a substantial portfolio of patents, trademarks, and know-how related to NR synthesis and applications. Niagen Bioscience maintains relationships with academic institutions, contract research organizations, and commercial partners to support clinical trials and product validation. Subsidiaries historically associated with the business include ChromaDex Spherix Consulting, Inc., though public disclosures indicate the company has narrowed its operational focus over time to concentrate on NAD⁺ science and commercialization.

Strategic Position & Investments

Strategically, Niagen Bioscience is focused on expanding the scientific validation, regulatory acceptance, and commercial adoption of NR as a foundational ingredient in healthy aging. Growth initiatives include increased investment in human clinical trials, expanded intellectual property protection, and broader global regulatory clearances. The company has publicly emphasized leveraging science-driven marketing and practitioner engagement to differentiate its products in a crowded supplement market.

The company has pursued selective acquisitions and technology investments historically, though recent strategy reflects capital discipline and concentration on core NAD⁺ assets rather than diversification. Notable investments are primarily internal, including expanded clinical research programs and process improvements for NR manufacturing. Niagen Bioscience is actively involved in emerging sectors related to longevity science, metabolic health, and mitochondrial function, though revenue contribution from emerging applications remains limited based on publicly available data.

Geographic Footprint

Niagen Bioscience is headquartered in the United States, with its principal executive offices in California. The company’s primary market is North America, which accounts for the majority of revenue through direct-to-consumer sales and domestic partnerships. Internationally, the company has established a presence in Europe, Asia-Pacific, and select other global markets through regulatory approvals, distribution partners, and ingredient customers.

While the company does not operate extensive physical infrastructure outside the U.S., its intellectual property, regulatory filings, and commercial relationships provide it with international reach. Regulatory approvals for NR in multiple regions have enabled sales and research collaborations abroad, contributing to the company’s global influence in the NAD⁺ supplement category.

Leadership & Governance

Niagen Bioscience is led by an executive team with experience in bioscience commercialization, consumer health, and intellectual property strategy. The company’s leadership emphasizes a science-led, evidence-based approach to product development and long-term value creation, with governance practices aligned to U.S. public company standards.

Key executives include:

• Rob Fried – Chief Executive Officer
• James Head – Chief Financial Officer
• Charles Brenner, Ph.D. – Chief Scientific Advisor
• Frank L. Jaksch, Jr. – Co-Founder & Director
• Damon Goodwin – General Counsel & Corporate Secretary

The board of directors includes company founders and independent directors with backgrounds in biotechnology, finance, and corporate governance. Leadership philosophy centers on protecting and monetizing scientific innovation while maintaining regulatory compliance and shareholder accountability.